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The mitogen activated protein kinase p38 plays a role in the receptor activator of NF-kB ligand (RANKL)-
induced osteoclast differentiation. In this study, we investigated the effect of p38 inhibitor doramapimod
on the osteoclast differentiation. Doramapimod signiﬁcantly inhibited the osteoclastogenesis of bone
marrow macrophages (BMMs) via attenuating the activation of p38 induced by M-CSF and RANKL.
Importantly, doramapimod blocked the migration and fusion in pre-osteoclasts via the down-regulating
NFATc1. The inhibitory effect of doramapimod on the migration/fusion of pre-osteoclasts via inhibiting
NFATc1 activity were conﬁrmed by measuring NFATc1 luciferase activity and evaluating the mRNA
expression of NFATc1-responsive genes related to the osteoclastic migration/fusion. These results sug-
gested anti-osteoclastogenic activity of doramapimod via inhibiting migration/fusion of pre-osteoclasts
and NFATc1 activity.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
The p38 mitogen-activated protein (MAP) kinase is one of the
best characterized kinases in the inﬂammatory process and many
pharmaceutical companies have tried to develop p38 inhibitors as
potential therapeutics for inﬂammatory diseases and cancers since
a decade ago (1, 2). As results of their effort, there are several p38
inhibitors under the clinical trials (Supplementary Table 1), but
relatively many p38 inhibitors have experienced to be failed in the
stage of development due to a lack of efﬁcacy in the clinical trials or
even withdrawn in the market. Lack of efﬁcacy has been also sug-
gested that they did not effectively target the disease or indication
for which they were intended (3). Therefore, ‘indication switching’
of failed drugs has been proposed in order to reduce the cost and
time required for new drug development. This approach is also
called to ‘drug repositioning’, ‘drug repurposing’, or ‘drug
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d/4.0/).drug candidates have been repositioned and evaluated for new
indications (4e6). The p38MAPK pathway plays a crucial role in the
receptor activator of nuclear factor-kB ligand (RANKL)-mediated
osteoclast differentiation and its druggability as a potential thera-
peutic target for inﬂammatory osteolysis have been suggested (7,
8). Apparently, the pharmacological inhibition of p38 has been
shown to strongly block the RANKL-induced differentiation of bone
marrow macrophages (BMMs) into osteoclasts (7).
Bone is dynamic tissue with continuous remodeling process by
osteoclastic bone resorption and osteoblastic bone formation.
Therefore, the tight regulation of bone remodeling is important to
maintain bone homeostasis. However, an imbalance by over-
activated osteoclasts or increased number of osteoclasts causes
bone resorption-related skeletal diseases including osteoporosis.
Bone resorption-related diseases are characterized by low bone
mass and microarchitectural deterioration of bone tissue, with a
high risk of bone fracture.
Strong p38 inhibitor doramapimod (Fig. 1A) has been originally
developed by Boehringer Ingelheim Pharmaceuticals Inc. for miti-
gating rheumatoid arthritis and Crohn's disease, but there was no
evidence for its clinical efﬁcacy in Crohn's disease (9). Since the
effect of doramapimod on the osteoclast differentiation has not
been studied yet, therefore, whether doramapimod could benese Pharmacological Society. This is an open access article under the CC BY-NC-ND
Fig. 1. Doramapimod inhibits RANKL-induced osteoclast differentiation by attenuating p38 activation. (A) The chemical structure of doramapimod. (B) BMMs were cultured with
the vehicle (DMSO) or indicated dose of doramapimod in the presence of RANKL (10 ng/ml) and M-CSF (30 ng/ml) for 4 days. Multinucleated osteoclasts were visualized to purple-
colored giant cells by TRAP staining. Stained cells were photographed under a light microscope (Magniﬁcation  100). (C) The number of TRAP-positive multinucleated osteoclasts
(TRAP-positive MNCs) with more than 5 nuclei (N  5) were counted. (D) TRAP activity was measured. (E) Viability of BMMs was evaluated by CCK-8 assay. (F) Effects of dor-
amapimod on RANKL-induced phosphorylation of JNK1/2 and p38 were evaluated byWestern blot analysis. BMMs were cultured for 1 days in the presence of M-CSF (30 ng/ml) and
starved for 2 h. After pretreated with DMSO or doramapimod (1 mM) for 2 h, cells were stimulated with RANKL (10 ng/ml) for indicated time. Total protein lysates (20 mg) were
separated in 10% SDS-PAGE gel and immunoblotted with indicated primary antibodies respectively. All data are representative of at least three independent experiments.
Densitometric analysis was performed using NIH ImageJ 1.43u software and the relative, normalized ratios of p-JNK1/2/JNK1/2, p-p38/p38 were presented. ###, p < 0.001 (versus
‘the group treated with the vehicle only’), **, p < 0.01; ***, p < 0.001 (versus ‘the group treated with RANKL only’).
S.-H. Moon et al. / Journal of Pharmacological Sciences 129 (2015) 135e142136applied to inhibit osteoclast differentiation was investigated in this
study.
2. Materials and methods
2.1. Materials
Doramapimod (BIRB796) was purchased from LC labs. (Woburn,
MA, USA) and was diluted with DMSO to make 10 mM DMSO stock
solution that was diluted with PBS before cell treatment. Therefore,
0.03% of DMSO was used as a vehicle control in all experiments.
Penicillin, streptomycin, cell culture medium, and fetal bovine
serum (FBS) were purchased from Gibco BRL (Grand Island, NY,
USA). Mouse soluble macrophage colony-stimulating factor (M-CSF) and recombinant mouse or human RANKL were purchased
from R&D Systems (Minneapolis, MN, USA) and diluted with sterile
phosphate buffered saline (PBS) containing 0.1% bovine serum al-
bumin (BSA) according to the manufacturer's protocol. Stock dilu-
tion was carried out by PBS. Cell viability assay kit, CCK-8 was
purchased from Dojindo Molecular Technologies (Rockville, MD,
USA). Primary antibodies against nuclear factor of activated T cells
c1 (NFATc1) and actin, and the secondary antibodies were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Pri-
mary antibodies against phosphorylated (p)-JNK1/2, JNK1/2, p-p38,
p38 were purchased from Cell Signaling Technology (Beverly, MA,
USA). NFATc1 luciferase reporter vector (NFAT-luc) and the control
pRL-Renilla control vector were purchased from Clontech (Moun-
tain View, CA, USA) and Promega (Fitchburg, WI, USA), respectively.
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This study was carried out in strict accordance with the rec-
ommendations in the Standard Protocol for Animal Study of Korea
Research Institute of Chemical Technology (KRICT; Permit No.
2012-7D-02e01). The protocol (ID No. 7D-M1) was approved by the
Institutional Animal Care and Use Committee of KRICT (IACUC-
KRICT). All efforts were made to minimize suffering, animal num-
ber, and stress/discomfort. In detail, after cervical dislocation, bone
marrow cells (BMCs) were obtained from 5-week oldmale ICRmice
(Damool Science, Daejeon, Korea) by ﬂushing femurs and tibias
with a-MEM supplemented with antibiotics (100 units/ml peni-
cillin and 100 mg/ml streptomycin). BMCs were cultured on a cul-
ture dish in a-MEM supplemented with 10% FBS with 10 ng/ml of
M-CSF for 1 day. Then, after non-adherent BMCs were replated on a
Petri dish and cultured for 3 days in the presence of M-CSF (30 ng/
ml), adherent BMMs were used for osteoclast differentiation. Then,
BMMs (1 104 cells/well in a 96-well plate or 3 105 cells/well in a
6-well plate) were seeded in triplicate and cultured in the presence
ofM-CSF (30 ng/ml) andmRANKL (10 ng/ml) for 2 or 4 days in order
to generate pre-osteoclasts or TRAPþ-MNCs.
2.3. TRAP staining and activity assay
MNCs were ﬁxed with 3.7% formaldehyde for 10 min, per-
meabilized with 0.1% Triton X-100 for 10 min, and stained with the
Leukocyte Acid Phosphatase Kit 387-A (SigmaeAldrich, St. Louis,
MO, USA). TRAPþ-MNCs with ﬁve or more nuclei were counted as
osteoclasts under a light microscope. To measure TRAP activity,
cells in a 96-well plate were ﬁxed with 3.7% formaldehyde for
10 min, permeabilized with 0.1% Triton X-100 for 10 min, and
incubated with 100 ml of citrate buffer (100 mM, pH 5.0) containing
50 mM sodium tartrate and 3 mM p-nitrophenylphosphate (Sig-
maeAldrich) at 37 C for 1 h. Reaction mixtures were transferred
into a new plate containing an equal volume of 0.1 N NaOH, and
optical density values were determined at 405 nm in Wallac
EnVision microplate reader (PerkinElmer, Waltham, MA, USA). All
experiments were performed in triplicate.
2.4. Cell viability assay
BMMs (1  104 cells/well) were seeded in a 96-well plate and
incubated for 1 day. Then, cells were treated with M-CSF (30 ng/ml)
and doramapimod. After incubation for 3 days, cell viability was
measured by CCK-8 assay kit according to the manufacturer's
protocol. All experiments were performed in triplicate.
2.5. Western blot analysis
Whole cells were lysed by the addition of cold lysis buffer
containing 0.2 M TriseHCl, pH7.5, 1.5 M NaCl, 1% deoxycholic acid,
1% NP-40 and 1 mM EDTA along with protease and phosphatase
inhibitors. The cell lyasates were subsequently incubated in 4 C for
20 min and then centrifuged at 14,000 g for 15 min. The protein
concentration of lysates was determined by protein assay kit (Bio-
Rad, Hercules, CA, USA) and the denatured proteins (20 mg) were
loaded on the 10% SDSePAGE, transferred to PVDF membrane
(Millipore, Bedford, MA, USA). After blocking with 5% nonfat skim
milk in TBST buffer (20 mM TriseHCl (pH 7.6), 137 mM NaCl and
0.1% Tween-20), the membrane was probed with the primary
antibody. Membranes were incubated for overnight at 4 C, washed
with TBST buffer at room temperature and incubated for 1 h with
anti-mouse, anti-rabbit and anti-goat immunoglobulin antibody
(1:5000) under the same conditions. After washing with TBST
buffer, the membranes were developed using the SuperSignal WestFemto Maximum Sensitivity Substrate kit (Pierce Biotechnology,
Rockford, IL, USA) according to the manufacturer's instructions and
visualized with LAS-3000 luminescent image analyzer (Fuji Photo
Film Co., Ltd., Tokyo). At least three independent experiments were
carried out.
2.6. Migration assay
The migration of pre-osteoclasts was evaluated using two
migration assay systems, the wound healing assay and the Boyden
chamber migration assay. For the wound healing assay, BMMs
(2  104 cells/well) were incubated with M-CSF (30 ng/ml) and
mRANKL (10 ng/ml) for 2 days in a bottom line-marked 96-well
ImageLock Microplate (ESSEN BioScience, Inc., Ann Arbor, MI,
USA) for the completed differentiation into pre-osteoclast. Then,
after wounds were made using a 96-well WoundMaker™ (ESSEN
BioScience, Inc.), cells were incubated with doramapimod. The
continuous kinetic outputs of migrated cells were analyzed every
2 h for 20 h using IncuCyte™ software. The relative wound healing
density (RWD) was calculated in comparison with that of cells
treated with the vehicle (DMSO, 0.1%).
For the Boyden chamber migration assay, a-MEM containing
10% FBS and doramapimod was added to the bottom of chamber,
whichwas then placed over the 0.01% gelatin-coated polycarbonate
membrane (8 mm pore size; Neuro Probe, Gaithersburg, MD, USA),
the silicone gasket, and the top chamber. Then, pre-osteoclasts
(2  104 cells/50 ml) derived from BMMs incubated in a culture
dish with M-CSF (30 ng/ml) and RANKL (10 ng/ml) for 2 days were
detached by scraper, resuspended in a-MEM containing 0.1% FBS,
M-CSF (30 ng/ml) and RANKL (10 ng/ml), incubated with dor-
amapimod for 30min and seeded into thewells of the top chamber.
After incubation at 37 C in 5% CO2 for 5 h, the migrated cells on the
lower side of membrane were ﬁxed and stained with Diff-Quick
(Dade Behring, Deerﬁeld, IL, USA). After the membrane was
placed and attached on a glass slide by 30% glycerol solution, the
migrated cells were photographed under amicroscopy and counted
in three randomly selected ﬁelds using NIH ImageJ 1.43u software.
All experiments were performed in triplicate.
2.7. NFATc1 luciferase activity assay
The full-length human RANK cDNA was ampliﬁed from human
leukocyte cDNA from Clontech and cloned into the HindIII-EcoRI
site of pcDNA3.1 (Thermo Fisher Scientiﬁc, Waltham, MA, USA).
For measuring NFATc1 transcriptional activity, human embryonic
kidney HEK293T cells were plated at a density of 5  104 cells/well
on a 48-well plate in triplicate for 2 days. Plasmids containing
NFAT-luc (100 ng/well), pcDNA3.1-RANK (100 ng/well), and pRL-
Renilla (20 ng/well) were transfected into HEK293T cells with
Lipofectamine 2000 (Thermo Fisher Scientiﬁc) according to the
manufacturer's protocol. After 6 h, transfected HEK293T cells were
treated with hRANKL (50 ng/mL) and doramapimod for 2 days. The
luciferase activity was detected in cell extracts with the Dual-
Luciferase Reporter Assay System (Promega) in Wallac EnVision
microplate reader. NFATc1 luciferase activity was normalized by
Renilla luciferase activity. All experiments were performed in
triplicate.
2.8. Real-time PCR
Total RNA was isolated using TRIzol reagent (Thermo Fisher
Scientiﬁc) according to the manufacturer's instruction. Equal
amounts of total RNA was reverse transcribed to cDNA using the
Omniscript RT kit (Qiagen, Valencia, CA, USA) and 1 mg of total RNA,
1 mM of oligo dT18 primer, 10 units of the RNase inhibitor, RNasin
Table 1
Primer sequences used in this study.
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sets (Table 1) used in this study was designed in an online primer
design program (10). Real-time PCR was then conducted in Stra-
tagene Mx3000P Real-Time PCR system with Brilliant SYBR Green
Master Mix (Stratagene, La Jolla, CA, USA) in 20 ml reaction mixture
containing 10 ml of SYBR Premix Ex Taq (Takara Bio, Inc., Otsu),
2 pmol of forward primer, 2 pmol of reverse primer, and 2 ml of
1:10-diluted ﬁrst strand 1 mg of cDNA. Ampliﬁcation parameters
consisted of an initial denaturation at 95 C for 10min and 40 cycles
of three-step PCR (a denaturation at 94 C for 40 s, an annealing at
53 C for 40 s, and an extension at 72 C for 1 min). All reactions
were performed in triplicate and data analyzed using the 2DDCT
method (11). Expression levels of the house keeping gene GAPDH
were used to control for differences in loading and cDNA synthesis
efﬁciency between samples.
2.9. Bone resorption assay
BMMs (1  104 cells) were seeded and cultured for 2 days to
differentiate into pre-osteoclasts in the presence of M-CSF (30 ng/Fig. 2. Doramapimod inhibits the middle stage of osteoclast differentiation. Inhibitory effe
BMMs were treated with doramapimod (1 mM) for the indicated times, and cultured for 4 da
TRAP. TRAP-positive MNCs were photographed under a light microscope (Magniﬁcation  1
RANKL only’).ml) and RANKL (10 ng/ml) on BioCoat Osteologic MultiTest slides
(BD Biosciences, MA, USA). Then, cells were treated with dor-
amapimod for 1 day. For measuring the area of resorbed pits, cells
were removed using 5% sodium hypochlorite for 5 min, and then,
after the plate was washed with PBS, the total resorption pits were
photographed under a light microscope and analyzed using NIH
ImageJ 1.43u software.
2.10. Statistical analysis
All quantitative values are presented as mean ± SD. Each
experiment was performed 3 times, and results from one repre-
sentative experiment shown. Statistical differences were analyzed
using ANOVA test in SPSS (Korean version 14.0). A value of p < 0.05
was considered statistically signiﬁcant.
3. Results
3.1. Doramapimod inhibits M-CSF and RANKL-induced osteoclast
differentiation of BMMs via p38 signaling pathway
Whether doramapimod inhibits osteoclast differentiation was
investigated using BMMs. When BMMs differentiated into TRAPþ-
MNCs by RANKL, doramapimod signiﬁcantly inhibited the forma-
tion of TRAPþ-MNCs (Fig. 1B and C). Anti-osteoclastogenic activity
of doramapimod was also conﬁrmed by measuring TRAP activity
(Fig. 1D). No cytotoxicity in BMMs by doramapimod was observed
at the concentrations used in this study (Fig. 1E). Cellular activity of
doramapimod to inhibit the activation of p38 was also conﬁrmedcts of doramapimod on RANKL-induced osteoclastogenesis of BMMs was reevaluated.
ys with M-CSF (30 ng/ml) plus RANKL (10 ng/ml). Then, cells were ﬁxed and stained for
00) and counted. *, p < 0.05; **, p < 0.01; ***, p < 0.001 (versus ‘the group treated with
S.-H. Moon et al. / Journal of Pharmacological Sciences 129 (2015) 135e142 139by Western blot analysis (Fig. 1F); doramapimod inhibited the M-
CSF and RANKL-induced phosphorylation of p38. In addition, the
M-CSF and RANKL-induced phosphorylation of JNK1/2 at 5minwas
weakly inhibited by doramapimod.
3.2. Doramapimod inhibits the middle stage of osteoclast
differentiation
To better understand when doramapimod inhibits osteoclast
differentiation, we re-evaluated its anti-osteoclastogenic activity by
culturing cells with it according to several different time schedules
as shown in Fig. 2. Interestingly, there were signiﬁcantly fewer
TRAPþ-MNCs with 5 nuclei formed when cells were treated with
doramapimod on 1 day after RANKL treatment and incubated for
another 1 day. In other words, the presence of doramapimod from 1
to 2 day after RANKL treatment most strongly inhibited the for-
mation of TRAPþ-MNCs.
3.3. Doramapimod inhibits migration of pre-osteoclasts
RANKL trigger the differentiation of BMMs into mononuclear
osteoclasts (pre-osteoclasts) and induce them to migrate until they
attach to the bone surface. Mononuclear osteoclasts then fuse with
each other to form giant multinucleated osteoclasts that subse-
quently mediate bone resorption. Our result showing that the
presence of doramapimod from 1 to 2 day after RANKL treatment
signiﬁcantly inhibited the formation of TRAPþ-MNCs suggested that
anti-osteoclastogenic activity of doramapimod could be due to its
potential to inhibit the migration and fusion of pre-osteoclasts.
Therefore, the effect of doramapimod on the M-CSF and RANKL-
induced migration of pre-osteoclasts was further investigated us-
ing twomigration assay system. Results of thewound-healing assayFig. 3. Doramapimod inhibits migration of pre-osteoclasts. The effect of doramapimod on t
chambers (B). The red and white dashed lines (A) represent the wounded area and the ed
resented as mean ± SD of the triplicates. The representative images were also presented. (
group’). (B) Boyden chamber assay was carried out as described in the ‘Materials and Met
(versus ‘the group treated with the vehicle only’). *, p < 0.05; ***, p < 0.001 (versus ‘the grand the Boyden chamber migration assay revealed that dor-
amapimodsigniﬁcantly inhibited themigrationof pre-osteoclasts in
a dose-dependent manner as shown in Fig. 3A and B, respectively.
3.4. Doramapimod inhibits activity of p38 and NFATc1, and mRNA
expression of gene related to migration and fusion in pre-osteoclasts
The p38-inhibitory activity of doramapimod in pre-osteoclasts
was conﬁrmed by Western blot analysis (Fig. 4A). Since NFATc1 is
a master transcription factor for the transcriptional up-regulation
of genes related to migration and fusion of pre-osteoclasts, our
suggestion that anti-osteoclastogenic action of doramapimod via
inhibiting p38 in pre-osteoclasts further affects the activity of
NFATc1 was evaluated by assessing the expression and activity of
NFATc1 and the mRNA expression levels of genes related to
migration and fusion of pre-osteoclasts. Western blot analysis
revealed that doramapimod dose-dependently inhibited the pro-
tein expression (Fig. 4A). RANKL signiﬁcantly induced the tran-
scriptional activity of NFATc1 in HEK293T cells transfected with
RANK plasmid and NFATc1 ﬁreﬂy-luciferase reporter plasmid, but
this induction was signiﬁcantly inhibited by doramapimod in a
dose-dependent manner (Fig. 4B). The real-time PCR also revealed
that doramapimod signiﬁcantly inhibited the mRNA expression
levels of NFATc1, the dendritic cell-speciﬁc transmembrane protein
(DC-STAMP), the d2 isoform of vacuolar (Hþ) ATPase V0 domain
(ATP6v0d2), and a disintegrin and metalloproteinase 8 (ADAM8) in
pre-osteoclasts (Fig. 4C).
3.5. Doramapimod inhibits the bone-resorbing activity in vitro
To examine whether doramapimod affects bone resorbing ac-
tivity, doramapimod was treated to pre-osteoclasts cultured onhe migration of pre-osteoclasts was evaluated using IncuCyte software (A) and Boyden
ge of migrated cells, respectively. Values (% RWD; Relative Wound Density) were rep-
Magniﬁcation  40) *, p < 0.05; ***, p < 0.001 (versus ‘the doramapimod-non-treated
hods’. Migrated cells were counted after staining. (Magniﬁcation  40) ##, p < 0.001
oup treated with 10% FBS in bottom chamber’).
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signiﬁcantly inhibited the area of resorbed pits in a dose dependent
manner, suggesting that doramapimod could inhibit the bone
resorption when it was treated during pre-osteoclasts were fully
differentiated into mature osteoclasts.
4. Discussion
The p38 signaling pathway plays a role in cell differentiation and
migration (12). Apparently, several studies have suggested the
involvement of p38 in osteoclast differentiation (13), and further-
more, the RANKL-mediated induction of NFATc1 during osteoclast
differentiation in the presence of M-CSF has been shown to be
mediated by the p38 signaling pathway (14).
Here, we found the anti-osteoclastogenic activity of dor-
amapimod; especially, it inhibited the migration/fusion of pre-
osteoclasts via the down-regulation of NFATc1 and its responsive
genes related to their migration and fusion. Most studies on the role
of p38 in cell migration have focused on the change of cytoskeleton
rather than in gene expression, but in this study, we suggested that
the inhibition of p38 by doramapimod could reduce the NFATc1
expression and activity, which further affect the transcription of its
target genes such as DC-STAMP and ATP6v0d2 (15, 16). Dor-
amapimod has been shown to block the migration of cornealFig. 4. Doramapimod inhibits activity of p38 and NFATc1, and mRNA expression of gene r
activation and NFATc1 expression the in pre-osteoclasts were evaluated by Western blot ana
and lysed in lysis buffer. Then, the lysates were analyzed by western blotting. Actin was used
software and the relative, normalized ratios of p-p38/p38 and NFATc1/actin were presented
luciferase activity assay as described in ‘Materials and Methods’. ##, p < 0.001 (versus ‘the hR
treated group’). (C) Effect of doramapimod on mRNA expression of osteoclast-speciﬁc genes
then mRNA expression levels were evaluated by real-time PCR. *, p < 0.05; **, p < 0.01; ***epithelial cells (17), but its effect on cell fusion and/or differentia-
tion has not been reported.
DC-STAMP is a keymolecule mediating fusion of pre-osteoclasts
(18, 19), and ATP6v0d2-deﬁcient mice exhibited impaired osteo-
clast fusion (20). The induction of osteoclast fusion by NFATc1 via
up-regulation of ATP6v0d2 and DC-STAMP has been reported (15),
and as an osteoclast stimulating factor, ADAM8 has been also re-
ported to enhance osteoclast precursor fusion (21, 22).
Similarly with our results, another p38 inhibitors have been
shown to inhibit the differentiation of BMMs into osteoclasts (23,
24), and furthermore, they also exhibited anti-arthritis activity by
mitigating joint degeneration and pain, and induced apoptosis of
cancer cells (25e27). In cancer cells, p38 inhibition exhibited
decreased in vivo bone metastasis (28), but conversely, its acti-
vation enhanced osteoclast maturation and bone resorption (29),
suggesting the involvement of cancer p38 in metastatic activation
of osteoclasts. In addition, among several potential therapeutic
targets to bone pain induced by cancer metastasis (30), cancer-
activated osteoclasts per se have been suggested to be targeted
(31, 32), and the anti-resorptive therapeutics such as
bisphosphonates and RANKL inhibitors have been approved as a
new classes of therapies to treat the patients with bone
metastasis-induced pain. In the clinical study of doramapimod in
neuropathic pain following nerve injury, its meaningful analgesicelated to migration and fusion in pre-osteoclasts. (A) Effects of doramapimod on p38
lysis. Brieﬂy, after doramapimod was treated into pre-osteoclasts, cells were harvested
as the internal control. Densitometric analysis was performed using NIH ImageJ 1.43u
. (B) Effect of doramapimod on the transcriptional activity of NFATc1 was evaluated by
ANKL-non-treated group’). *, p < 0.05; **, p < 0.01; ***, p < 0.001 (versus ‘the hRANKL-
were evaluated. Brieﬂy, pre-osteoclasts were treated with doramapimod for 1 day, and
, p < 0.001 (versus ‘the doramapimod-non-treated group’).
Fig. 5. Doramapimod inhibits osteoclastic bone resorption. (A) Pre-osteoclasts were
cultured on hydroxyapatite-coated plates for 1 days with the indicated concentrations
of doramapimod. Attached cells on the plate were removed and photographed under a
light microscope. (B) Pit areas were measured using NIH ImageJ 1.43u software.
***, p < 0.001 (versus ‘the doramapimod-non-treated group’).
S.-H. Moon et al. / Journal of Pharmacological Sciences 129 (2015) 135e142 141effect has been reported (33). Therefore, although the clinical
evaluation of doramapimod in the original indication has been
failed, the pharmacological p38 inhibition could be beneﬁcially
applied into several therapeutic indications including inﬂamma-
tory diseases and cancer as well as osteoclast-related disorders
even though there are a variety of anti-osteoclastic natural
products (2,34e36).
In addition, doramapimod inhibited the RANKL-induced phos-
phorylation of JNK1/2 at 5 min, because doramapimod has been
reported to inhibit JNK as well as p38 (37), but its inhibitory activity
against JNKs (Kd ¼ 7.3e9100 nM) was less than that against p38s
(Kd ¼ 0.45e78 nM). In this study, we focused on the functional role
of doramapimod as an inhibitor of p38, but considering that dor-
amapimod has been shown to inhibit other kinases, we might not
exclude the possibility that anti-osteoclastogenic activity of dor-
amapimod could be due to its potential to inhibit other kinases that
are not studied here. This possibility would be experimentally
proved in a further study.
In summary, here we suggested anti-osteoclastogenic activity of
doramapimod via inhibiting migration/fusion of pre-osteoclasts
and NFATc1 activity, and proposed to keep continuous efforts to
access the efﬁcacy and safety of p38 inhibitor in clinical trials for
creating their clinical therapeutic values.Conﬂicts of interest
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